Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Phase 2 trial evaluates entospletinib in DLBCL

Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331

Key clinical point: Entospletinib has limited activity against relapsed/refractory diffuse large B-cell lymphoma and a high rate of adverse events.

Major finding: The rate of progression-free survival at 16 weeks was 3.6% with a median PFS of 1.5 months.

Study details: An analysis of 43 relapsed/refractory DLBCL patients who received single-agent entospletinib.

Disclosures: The study was supported by Gilead Sciences. Dr. Burke reported relationships with Gilead and other companies.

Read the article here.

Citation:

Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331.

This Week's Must Reads

Caplacizumab approved for adults with aTTP , FDA news release: FDA approves first therapy for the treatment of adult patients with a rare blood clotting disorder

IVIG versus anti-D in pediatric ITP , Lioger B et al. J Pediatr. 2019; 204:225-33.

Promising treatment for heavy menstrual bleeding , O’Brien SH et al. J Pediatr Adol Gynec. 2019 Feb 4. doi: 10.1016/j.jpag.2019.01.009.

Beware of ICH in severe hemophilia cases , Zwagemaker AF et al. EAHAD 2019, Abstract OR08.

75 exposure days is the magic number in inhibitor risk , van den Berg HM et al. EAHAD 2019, Abstract OR05.

Must Reads in Aggressive Lymphomas

Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology

Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21

Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

5F9 plus rituximab looks durable in NHL, Advani R et al. N Engl J Med. 2018;379:1711-21

Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025